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Abstract
Background: Life trauma is highly prevalent in the general population and posttraumatic stress
disorder is among the most prevalent psychiatric consequences of trauma exposure. Brazil has a
unique environment to conduct translational research about psychological trauma and
posttraumatic stress disorder, since urban violence became a Brazilian phenomenon, being
particularly related to the rapid population growth of its cities. This research involves three case-
control studies: a neuropsychological, a structural neuroimaging and a molecular neuroimaging
study, each focusing on different objectives but providing complementary information. First, it aims
to examine cognitive functioning of PTSD subjects and its relationships with symptomatology. The
second objective is to evaluate neurostructural integrity of orbitofrontal cortex and hippocampus
in PTSD subjects. The third aim is to evaluate if patients with PTSD have decreased dopamine
transporter density in the basal ganglia as compared to resilient controls subjects. This paper shows
the research rationale and design for these three case-control studies.
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BMC Psychiatry 2009, 9:30 http://www.biomedcentral.com/1471-244X/9/30Methods and design: Cases and controls will be identified through an epidemiologic survey
conducted in the city of São Paulo. Subjects exposed to traumatic life experiences resulting in
posttraumatic stress disorder (cases) will be compared to resilient victims of traumatic life
experiences without PTSD (controls) aiming to identify biological variables that might protect or
predispose to PTSD. In the neuropsychological case-control study, 100 patients with PTSD, will be
compared with 100 victims of trauma without posttraumatic stress disorder, age- and sex-matched
controls. Similarly, 50 cases and 50 controls will be enrolled for the structural study and 25 cases
and 25 controls in the functional neuroimaging study. All individuals from the three studies will
complete psychometrics and a structured clinical interview (the Structured Clinical Interview for
DSM-IV and the Clinician-Administered PTSD Scale, Beck Anxiety Inventory, Beck Depression
Inventory, Global Assessment of Function, The Social Adjustment Scale, Medical Outcomes Study
36-Item Short-Form Health Survey, Early Trauma Inventory, Clinical global Impressions, and
Peritraumatic Dissociative Experiences Questionnaire). A broad neuropsychological battery will be
administered for all participants of the neuropsychological study. Magnetic resonance scans will be
performed to acquire structural neuroimaging data. Single photon emission computerized
tomography with [(99m)Tc]-TRODAT-1 brain scans will be performed to evaluate dopamine
transporters.
Discussion: This study protocol will be informative for researchers and clinicians interested in
considering, designing and/or conducting translational research in the field of trauma and
posttraumatic stress disorder.
Background
Posttraumatic stress disorder (PTSD) occurs following
exposure to a potentially traumatic life event and is
defined by three symptom clusters: reexperiencing, avoid-
ance and numbing, and arousal [1]. However, PTSD is rel-
atively rare event in trauma-exposed people. This fact has
motivated research aimed at identifying risk factors for
this disorder. Two meta-analyses of PTSD risk factors have
come to some consensus as to the key factors influencing
PTSD vulnerability. These include small but consistent
effects on risk for pre-trauma factors such as cognitive
ability, family psychiatric history, pre-trauma psychologi-
cal adjustment, child abuse, other previous trauma expo-
sures, and general childhood adversity [2,3].
Characteristics of the traumatic experience were found to
be particularly important, especially trauma severity, per-
ceived life threat and peri-traumatic emotional reactions
such as dissociation [2,3]. A dose-response relation
between severity of exposure and conditional risk of
developing PTSD has been well-documented [4,5]. Post-
trauma social support also appears to play a role [2,3].
However, the risk factors models supported by meta-ana-
lytic studies explain only about 20% of the variance in
PTSD; clearly new variables need to be incorporated into
models of PTSD vulnerability. Due in part to methodolog-
ical limitations of extant research, the role of neuropsy-
chological and brain structure and functional factors in
the etiology of PTSD are less well understood.
This paper describes the protocol for the Project Post-
Traumatic Stress Disorder in Brazil which is aimed at char-
acterizing the underlying biology of PTSD neuropsycho-
logical assessment, neurostructural evaluation and
molecular imaging of the dopamine transporter system.
Brazil offers a unique environment to conduct transla-
tional research about psychological trauma and PTSD.
From 1980 to 2000, a total of more than 598 thousand
people died in Brazil because of homicide with two thirds
of this occurring in the 90's. In 1980 the leading cause of
violent death in the country was traffic accidents but in
2000 it was homicides [6,7]. From 1991 to 2000 there was
an increase of 27% in the proportion of deaths caused by
homicides among the total deaths in the country. Thus,
lethal violence became a national phenomenon, being
particularly related to the rapid population growth of
large and urban cities [8].
Neuropsychological findings in PTSD
PTSD is characterized by re-experiencing of the traumatic
event and the inability to consciously recall facts about the
traumatic event as well as by altered emotional processing
of trauma-relevant cues. The patient's memory seems to
be fixed on the traumatic event, and the retrieval of others
memories seems to be inhibited [9-11]. Previous research
on the neuropsychology of PTSD has identified several
neurocognitive deficits [12]. Neuropsychological meas-
ures of intellectual ability, learning, memory (verbal and
non-verbal), attention, visuospatial ability, executive
functioning, language, psychomotor speed have been
examined. Several studies have identified impaired per-
formance on verbal memory and learning in PTSD cases
as compared to controls [13-16]. Other studies have doc-
umented differences between cases and controls in differ-
ent domains, including attention, working memory [17-Page 2 of 12
(page number not for citation purposes)
BMC Psychiatry 2009, 9:30 http://www.biomedcentral.com/1471-244X/9/3022], and processing speed [21]. Although there is evidence
for memory impairment in PTSD subjects, it remains
unclear whether memory impairment is confined to ver-
bal material or nonverbal material is also affected
[11,14,21]. Different studies, have found impaired visual
memory in individuals with PTSD [18,19,23,24].
Many studies have shown impairments in the whole mne-
monic process (immediate memory, recall and recovery),
attention, learning, intellectual level, and emotional
processing [25]. Nonetheless, others studies have shown
no differences between cases and controls for memory
[24,26-29] and/or attention performance [12,13,30].
Those neuropsychological findings suggest involvement
of two primary strcutures: hippocampus and prefrontal
cortex. Several studies have reported decreases in hippoc-
ampal volume [31-36] and hippocampal N-acetylaspar-
tate [37-39] as well as an association between
hippocampal atrophy and poor verbal memory in PTSD
subjects [23]. Neurofunctional studies have indicated spe-
cific findings in limbic regions, although the relationship
of these results to neuropsychological performance
remains to be explored [40].
An alternative model of PTSD may be related to a dysfunc-
tion of higher-level attentional resource which in turn
might affect activity in other systems concerned with
memory and thought [20,41,42]. Attention and concen-
tration difficulties appear to be core deficits in PTSD and
memory deficits might actually be secondary to an
impaired attention. A possible explanation for the associ-
ation between memory and attention difficulties in PTSD
is that explicit memory performance may be impacted by
impaired attention resources during processing. Some
researchers have theorized that the heightened emotional
reactivity in patients with PTSD disrupts attentional
resources [43]. Impaired attention prevents sufficient reg-
istration of information, which in turn prevents consoli-
dation and retrieval of memory. Furthermore, recent
studies have demonstrated a possible deficit in the inhib-
itory processes of memory in PTSD [18,19,44].
Several potential confounding factors must be considered
for neuropsychological evaluation of PTSD patients
including comorbid depression, substance abuse, and
medical conditions, type of trauma, and motivational
aspects. Therefore, any conclusion if deficits observed are
specifically related to PTSD should take into account alter-
native explanations such as the possible effect of con-
founding factors [26,40]. In conclusion,
neuropsychological functioning has emerged as promis-
ing endophenotype to be explored in PTSD.
Neurostructural findings in PTSD
One of the possible mechanisms underlying the physio-
pathology of PTSD is the damaging action of glucocorti-
coids on hippocampus [45]. The hippocampus plays a
central role in neuropsychological functions such as
memory and emotional behaviour and is likely to be
involved in the development of PTSD. An alternative
model would be a failure in the regulatory activity of pre-
frontal cortex over amygdala, with a consequent hyperac-
tivity of the later in response to traumatic memories [46-
48]. This inhibitory deficiency is also a possible explana-
tion for the hyperexcitability symptoms found in PTSD.
The orbitofrontal cortex, the ventral portion of prefrontal
cortex, appears to be central in the regulation of prefrontal
cortex over amygdala and is also implicated in the
processing of negative emotion [49]. Studies using differ-
ent techniques have consistently found neurofunctional
abnormalities in this region in PTSD patients [50-52]. Fur-
thermore, some symptoms that may be seen in PTSD,
such as poor impulse control and violent assaults, are also
reported in individuals with lesions in orbitofrontal cor-
tex [53,54]. Findings from magnetic resonance imaging
studies have suggested neurostructural alterations in
PTSD. Although these findings are less consistent than
those seen in neurofunctional studies, volumetric reduc-
tions in hippocampus [23,32,34-36,51,52] and prefrontal
regions [55,56] have been reliably found. However, addi-
tional studies are still warranted in order to assess whether
these structural abnormalities are specific to PTSD or rep-
resent non-specific morphological abnormalities associ-
ated to trauma exposure. Further examination of
abnormalities in frontolimbic structures are also required
to clarify the role of structural and functional brain abnor-
malities in the pathophysiology of PTSD.
Molecular imaging of dopamine transporter in PTSD
Physiological response to stressful experience involves a
vast neural-endocrine-immunologic reaction that leads to
the release of catecholamines and autonomic nervous sys-
tem stimulation [57]. Noradrenergic and hypothalamus-
pituitary-adrenal axis systems are the most common stud-
ied in response to stress [58] but many other neural-chem-
ical systems are implicated. In animal studies,
dopaminergic innervation of the basolateral nucleus of
the amygdala, the medial prefrontal cortex and other lim-
bic regions is highly responsive to stress and may be
altered by stress [59-61]. Also the enhancement of the
acoustic startle response, which can be a symptom of
PTSD, has been related to the dopamine D1 receptor ago-
nists in rats [62]. Genetically determined alterations in
dopamine release and dopamine receptor expression in
mice have been implicated in behavioral abnormalities
induced by chronic stress [63]. This finding was inter-
preted as suggesting that stress-induced alterations of cen-
tral dopaminergic neurotransmission may be genotype-Page 3 of 12
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showed that there was a relationship between urinary
excretion of dopamine and plasma dopamine and (the
severity of) PTSD symptoms [64].
Evidence from genetic studies has proposed that reduced
density of D2 dopaminergic receptor predisposes to PTSD
[65]. There are two important PTSD candidate genes that
directly affect the dopamine system: the dopamine recep-
tor gene (DRD2) and the dopamine transporter (DAT)
gene. The D2 dopamine receptor (DRD2) minor (A1)
allele DRD2 A1 has already been linked to ADHD,
Tourette's syndrome, conduct disorder and substance
abuse [66]. This prompted suppositions that this gene
may be involved in stress response in humans [61]. Poly-
morphism of the dopamine transporter (DAT) gene, in
the locus SLC6A3 3' (VNTR), has been found to predis-
pose to PTSD and to chronic forms of the disorder [67].
Taken together, these evidences suggest a relevant role for
dopamine in the pathogenesis of PTSD.
To gain more clarity about any link between PTSD and the
DAT, it is therefore important to clearly document PTSD
patients, controlling confounders as alcohol consump-
tion, major depression and clinical illness, through a
functional neuroimaging investigation.
Although molecular imaging allows reliable information
on in vivo dopaminergic function [68], no studies, to our
knowledge, has examined dopaminergic system activity in
PTSD patients using molecular neuroimaging techniques.
The main reasons that justify such an effort to understand
the problem of violence and its consequences for mental
health can be described as follows: 1) Treatment strategies
to be sponsored by the Brazilian public health care system
need to be based on solid local data on the extent and
nature of the disorder; 2) Exposure to traumatic life events
is related to not only with mental disorders which include
PTSD and depression, but also with other cognitive and
neurotransmission dysfunctions [18,19,44,69]. The
impact in mental health of the population of exposure to
violence among the population of Sao Paulo, a large
urban centre in a Middle Income Country (MIC), as well
as specific parameters such as neurocognitive, neurostruc-
tural anf functional neuroimaging finds is virtually
unknown.
The subjects of the study will be selected from an epidemi-
ological/genetic survey in the city of Sao Paulo to assess
the relationship between exposure to violence and the
prevalence of PTSD and common mental disorders. Sub-
jects located in the epidemiological/genetic survey will be
referred to these three case-control studies, reported here,
and to a randomized controlled clinical trial on the effi-
cacy of topiramate for the treatment of PTSD symptoms.
This protocol is the result of collaborative task force to
conduct translational research in the field of traumatic
stress in urban regions of Brazil. The current project inves-
tigates possible causes for neurocognitive deficits, neu-
rostructural changes and dopaminergic dysfunction in
individuals with PTSD. We will be comparing individuals
with current or lifetime diagnosis of PTSD with those who
were exposed to a traumatic event but did not develop a
current or a lifetime diagnosis of PTSD.
The main objectives of this project are:
1. to examine cognitive functioning of PTSD subjects and
its relationships with symptomatology;
2. to evaluate neurostructural integrity of orbitofrontal
cortex and hippocampus in PTSD subjects;
3. to evaluate if patients with PTSD have decreased
dopamine transporter density in the basal ganglia as com-
pared to resilient controls subjects.
Methods and design
Sample
Cases and controls will be identified through an epidemi-
ologic survey conducted in the city of São Paulo. Details
of the epidemiologic study are presented in a companion
paper (cite) and are summarized here. To identify trauma
victims in the community, interviews were conducted by
a professional team specialized in household surveys, the
Brazilian Institute of Public Opinion and Statistics. Inter-
viewers were trained at the CIDI [70] in the Federal Uni-
versity of São Paulo, an accredited center by the World
Health Organization (WHO). Training procedures were
conducted in accordance to the guidelines set up by the
WHO. Interviews were carried out in the participants
households by means of printed questionnaires. All ques-
tionnaires were translated into Portuguese and adapted to
the local social and cultural context. Inclusion and exclu-
sion criteria for the three case-control studies are
described in tables 1 and 2, respectively. Individuals who
met inclusion criteria during the epidemiologic study
were invited to participate in the case-control study. Sub-
jects exposed to traumatic life experiences resulting in
PTSD (cases) will be compared to resilient subjects vic-
tims of traumatic life experiences without PTSD (controls)
aiming to identify biological variables that might protect
or predispose to PTSD. This case-control design will enrol
representative subjects from the community being this
procedure an important technique to overcome Berkson
bias. Subjects will be informed about the procedures of
the studies and will be asked to formally consent willing-Page 4 of 12
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Table 1: Inclusion criteria for PTSD cases (p) and control (c) groups
Neuropsychological Study Structural Neuroimaging study Molecular Neuroimaging study
p C P c p c
Age between 18 and 60 (inclusive) X X X X X X
Life time history of traumatic life experience as 
defined in criteria A of DSM IV criteria for PTSD
X X X X X X
PTSD diagnosis according DSM IV criteria as 
assessed by SCID I applied by trained psychiatrists 
or psychologists
X X X
Good general health with no additional diseases 
expected to interfere with the study
X X X X X X
Able to understand and signed informed consent X X X X X X
Completed 5 years grades of education X X
Fluent in Portuguese X X X X X X
Willing and able to complete all assessments X X X X X X
Willing to undergo neuroimaging (MRI) X X
Willing to undergo neuroimaging (SPECT) X X
Table 2: Exclusion criteria for PTSD cases (e) and control (c) groups
Neuropsychological study Structural Neuroimaging study Molecular Neuroimaging study
p c p c P c
Any significant neurologic disease, such as 
Parkinson's disease, multi-infarct dementia, 
Huntington's disease, normal pressure 
hydrocephalus, brain tumor, progressive 
supranuclear palsy, seizure disorder, subdural 
hematoma, multiple sclerosis, or history of 
significant head trauma followed by persistent 
neurologic defaults or known structural brain 
abnormalities.
X X X X X X
Any significant systemic illness or unstable medical 
condition
X X X X X X
History of significant head trauma followed by loss 
of consciousness
X X
Presence of pacemakers, aneurysm clips, artificial 
heart valves, ear implants, metal fragments or 
foreign objects in the eyes, skin or body.
X X
Claustrophobia X X
Current use of psychoactive medications such as 
antidepressants, neuroleptics, anxiolytics or 
sedative hypnotics and mood stabilizers.
X X X X
History of the following psychiatric disorders: 
schizophrenia, schizoaffective disorder, delusional 
disorder, bipolar affective disorder and depressive 
disorder with psychotic features (DSM IV criteria)
X X X X X X
Tremor or dystonia in the cephalic region that 
unable the scanning procedure for imaging 
acquisition
X X X X
BMC Psychiatry 2009, 9:30 http://www.biomedcentral.com/1471-244X/9/30ness to participate. Subjects who consent to participate in
the case-control studies will receive the following assess-
ment:
Measures
Clinical and Demographic assessment
1) Sociodemographic data will be obtained based by
using an adapted form of the CIDI sociodemographic sec-
tion;
2) Structured Clinical Interview for DSM-IV (SCID) I:
SCID is a semi structured interview for the DSM-IV
[71,72]. It allows the diagnosis of mental health disorders
according to DSM IV criteria and has already been vali-
dated for Brazilian population [73];
3) Clinician Administered PTSD Scale (CAPS) [74]: A cli-
nician rating scale for assessing current and lifetime PTSD:
the CAPS-1. CAPS is a structured clinical interview
designed to be applied by clinician and its validation was
included as part of the first phase of this protocol. It is a
30 items scale investigating the frequency and intensity of
PTSD symptoms and traumatic life experiences.
4) Beck Anxiety Inventory (BAI): BAI is a self-adminis-
tered 21 items questionnaire assessing intensity of anxiety
symptoms [75];
5) Beck Depression Inventory (BDI) is used to assess
depressive symptoms in clinical settings [108]; it is a self-
administered 21 items questionnaire, and it has been val-
idated for the Brazilian population [76];
6) Global Assessment of Function (GAF) scale provides
data on the clinical global state of patients [77];
7) The Social Adjustment Scale (SAS) is a self-adminis-
tered instrument to assess social adaptation [78,79] and it
has been validated to the Brazilian social and cultural con-
text [80];
8) Medical Outcomes Study 36-Item Short-Form Health
Survey (MOS SF-36) [81] is a self-report scale constructed
to collect data on health status, functioning, and well-
being. A Portuguese version of the questionnaire has
already been tested for its validity and reliability in Brazil
[82];
9) Early Trauma Inventory (ETI) is a semi-structured inter-
view comprising 56 items to measure traumatic life expe-
riences occurred in early life, in the following domains:
sexual, physical and psychological abuse and other trau-
matic life experiences [83];
10) Clinical global Impressions (CGI) is a scale to assess
treatment response in patients with mental disorders [84];
11) Peritraumatic Dissociative Experiences Questionnaire
(PDEQ) [85] is a reliable and valid measure of peritrau-
matic dissociation as previously described in the epidemi-
ologic study section.
The Neuropsychological Assessment
The neuropsychological evaluation will be performed in a
single session by neurophysiologists trained in the instru-
ments listed as follows. The training has been conducted
by a senior psychologist, acquainted to the assessments
chosen for the study, who will be responsible for supervis-
ing the trainees in order to keep the accuracy of measure-
ments. The following tests will be part of the
Neuropsychological Assessment:
1) The Wisconsin Card Sorting Test (WCST) will be used
to assess cognitive set shifting and executive functions
[86];
2) Vocabulary and Blocks – Subscales WAIS III is a widely
used measure for intellectual level[87];
3) The Digit Span – Subscale WAIS III is an important tool
for evaluating working memory and short-term mem-
ory[87];
4) The Spatial Span – Subscale WMS III is meant for
assessment of immediate nonverbal memory and nonver-
bal working memory[87];
5) The International Affective Picture System (IAPS) was
validated in Brazil and measures visual memory and emo-
tional reaction through positive, negative and neutral fig-
ures [87];
6) The Rey Auditory-Verbal Learning Test (RAVLT)
assesses the verbal learning and memory [88]
7) The Stroop Test is designed to assess selective attention
and cognitive flexibility[89]
8) The Visual Reproduction – Subscale WMS III assess vis-
ual memory[87];
9) Cancellation of Mensulan assesses selective visual
attention, vigilance and visual neglect[90];
10) Social and Occupational Functioning Assessment
Scale (SOFAS) [1] – Assess the social and occupational
functioning in the community.Page 6 of 12
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Imaging data will be acquired at the Instituto do Sono,
Federal University of Sao Paulo, using a GE1.5-T Signa
scanner. Structural MR images will be acquired using a
sagittal T1 acquisition series (TR = 9.8 ms, TE = 3.1 ms, flip
angle = 30°, NEX = 1, matrix size = 256 × 256, FOV = 24
cm, thickness = 1.0 mm). A T2-weighted image series will
also be acquired. Before scanning, a sagittal scout series
(nine to eleven 5-mm-thick slices with a 1-mm interslice
gap) will be performed to determine image quality and
clarity as well as subject head position. Measurements will
be conducted on PC workstation with the aid of BRAINS2
software [91]. Before tracing, T1- and T2-weighted images
will be spatially realigned so that the brain anterior-poste-
rior axis is parallel to the intercommissural line, which
was horizontal in the sagittal plane, and the interhemi-
spheric fissure is vertical in the axial plane. Six brain-lim-
iting points (anterior, posterior, superior, inferior, left,
and right) will then be picked to place images into the
standard Talairach three-dimensional space [92]. After
coregistering and fitting the three image sequences, a mul-
timodal tissue classification will be performed using a
Bayesian classifier based on discriminant analysis. This
segmentation method automatically generates thresholds
permitting the discrimination of grey and white matter as
well as cerebrospinal fluid.
Hippocampus
The hippocampus will be traced manually on the coronal
plane as described by Pantel et al [93]. Tracings begin with
the generation of auxiliary guideline traces on the sagittal
plane. The auxiliary traces are necessary to provide a neu-
roanatomically correct separation of rostral and caudal
parts of the hippocampus from adjacent nonhippocampal
brain tissue. Tracing will begin on the most medial slices.
The starting slice is identified by choosing the slices that
(going from medial to lateral) first show the cerebral
peduncle separated from the upper pons. Once the ante-
rior border of the hippocampus is identified on the start-
ing slice, the vertical crosshairs will be placed anteriorly to
this border. This procedure facilitates the identification of
the anterior border on the following slices, because the
head of the hippocampus, in general, does not extend
beyond this level on the more lateral slices. The anterior
border is outlined by the alveus and the uncal recess,
which may be obliterated. Dorsally, CSF of the temporal
horn of the lateral ventricle outlines the body, whereas the
pulvinar thalamus serves as the border for the tail. On the
medial slices the body is bordered by the fimbria, which
is excluded from the trace itself. The posterior border is
formed by the CSF of the lateral ventricle. The ventral bor-
der is defined by the WM of the temporal lobe.
Orbitofrontal cortex
The orbitofrontal cortex (OFC) will be outlined according
to the proposed geometrical method developed by Lac-
erda et al [49]. The OFC will be manually measured in the
coronal plane. The tip of the genu of corpus callosum will
be located in the sagittal plane and used as the most pos-
terior slice to be traced in the coronal plane. The last slice
traced will be the most anterior coronal slice where brain
tissue can be identified. The superior limit will be divided
in two parts to reflect more the actual anatomical bound-
ary of the OFC. In the subgenual regions, and specifically
from the tip of the genu to the most anterior part of the
CC, the superior boundary will be represented by the infe-
rior border of the anterior cingulate corresponding to a
midpoint at the interhemispheric fissure about five slices
(5.08 mm) below the intercommissural line. More anteri-
orly, and specifically in the slices ahead of the genu of the
CC, the superior limit will be represented by a midpoint
placed on the intercommissural line. This "lowering" of
the superior limit will be done to avoid inclusion of sub-
genual structures in the first slices that are not tradition-
ally considered to be part of OFC (e.g., anterior cingulate).
In all slices, horizontal and vertical crosshairs will be
placed as tangent lines at the inferior and lateral surfaces
of the frontal lobes, respectively. The intersection of these
two lines (horizontal and vertical crosshairs) will generate
two lateral points that will be connected to the superior
limit point, composing the lateral boundaries of the trac-
ings. The inferior border will be traced following the infe-
rior surface of the frontal lobes between the two lateral
boundaries described above. The OFC will also be subdi-
vided into gyrus rectus and orbital gyri by tracing a line
through the olfactory sulcus. This subdivision will not be
conducted in the most anterior slices where the olfactory
sulcus disappears.
SPECT scans of Dopamine Transporter
The kits of TRODAT-1 were obtained through a scientific
collaboration with the Research Institute of Nuclear
Energy, Lung-Tan, Taiwan. The metastable technetium-99
was produced by a generator of [99Mo] (molybdenum-
99) from the Institute of Nuclear Energy Research (IPEN-
SP) with freshly elution. The kits of TRODAT-1 were
marked with [99mTc] according to the technique devel-
oped by Kung et al[94]. Sixty mCi of elution of Sodium
Pertechnetate [99mTc] diluted in 5 ml of saline solution
are injected in the kit and submitted to 16 atmospheres
and temperature of 120°C, during 30 minutes in an auto-
clave. Later, the solution of [99mTc] TRODAT-1 is cooled
at room temperature.
The images will be acquired through a single photon
emission computerized tomography (SPECT) Gama cam-
era of the type (Hawkeye General Electric Medical System,Page 7 of 12
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[95]. All subjects will receive an intravenous injection of 2
ml containing among 22 to 25 mCi of [99mTc]-TRODAT-
1 in an antecubital peripheral vein. Images will be
acquired 4 hours after the injection. The SPECT modality
of the system with two heads and fan-beam collimators of
ultra-high resolution will be used. Energy Window will be
140 ± 14 keV and matrix of 128 × 128 in circular orbit
with step and shoot movements of 64 steps for each head
will be used, with diameter and degree of rotation of 30
cm and 360°, respectively. The time of acquisition for the
projection will be of 20 seconds, with a factor of zoom of
1.45. The reconstruction of the SPECT images will be
accomplished through a filter algorithm of filtered retro-
projection and a Butterworth filter of 0.4 cut off with pix-
els of 10th order. Three-dimensional images of the whole
brain will be obtained and, for the analysis, two transaxial
slices will be used at the level of the striatal body, with 3
mm of thickness corresponding to the level of the largest
captation of the radiotracer. DAT density will be calcu-
lated with binding potential (DAT-BP) using regions of
interests (ROI) bilaterally drawn in the striatum (STR)
and the occipital cortex (OCC-background). BP will be
calculated with the formula striatum (STR-OCC)/OCC.
Data management and Analyses
1) Questionnaires will be double typed and data will be
entered on SPSS software data files. Participants will be
divided into two categories, according to the diagnosis:
(1) lifetime diagnosis of PTSD and (2) Traumatic experi-
ence, but no lifetime diagnosis of PTSD. The following
comparisons will be carried out in the two groups:
1) Neuropsychological Study: neuropsychological
measures of PTSD cases compared to controls;
2) Magnetic resonance imaging study: to assess neu-
rostructural abnormalities in OFC and hippocampus
of patients with PTSD compared to resilient controls;
3) Molecular neuroimaging study: dopamine trans-
porter density using single photon emission tomogra-
phy of PTSD cases compared to controls.
Data will be codified and analyzed using the Statistical
Package for Social Sciences (SPSS for Windows, version
15.0). Proportion differences will be compared using the
Chi Square test or Fisher's exact test, as appropriate. Con-
tinuous variables will be compared by Analysis of Vari-
ance (ANOVA) or Mann-Whitney test for non-parametric
data. All significant tests will be considered as 2-tailed. P
values < 0.05 will be considered statistically significant.
Because of the exploratory nature of the study, we do not
consider alpha adjustment in multiple comparisons and
we did not calculate the sample size (Table 3). The main
analyses will examine the relationship between exposure
to traumatic events and the PTSD occurrence. Unadjusted
relative risk for studied variables cognition, cortisol level,
hippocampal volume, and dopamine transporter density
(and 95% confidence intervals) are presented for trauma
without PTSD and trauma with PTSD, both with and
without adjustment for age (18–29 years, 30–39 years,
40–49 years, 50–60) and gender. As a secondary analysis,
we will be adjusting for clinical and demographic varia-
bles previously associated with PTSD: marital status,
country of birth, socio-economic status, urbanicity and
employment status.
Ethical Issues
Participants will be informed about research procedures
and risks and signed an informed consent submitted and
approved by the Ethical Committee of the Federal Univer-
sity of São Paulo (Processes: 1-Neuropsychology-0124/
06; Neurostructural-1026/06; Molecular neuroimaging-
0295/06). Subjects diagnosed as having any mental
health disorder will be offered a referral to the out-patient
clinic at the Federal University of Sao Paulo.
Discussion
This study protocol illustrates a collaborative work of
potential value to researchers interested in innovative and
realistic investigation aimed at understanding the neuro-
biology of PTSD in a population-representative sample.
This article describes the methodological responses to
challenges in conducting translational research, where
patients are identified from a real-world scenario in a pop-
ulation-based study and go through neuropsychological,
neurostructural and molecular neuroimaging techniques.
A recent review of the literature found over 60 studies
examining memory and attention performance in PTSD
subjects, but few studies have examined learning, execu-
Table 3: Sample size in each study for PTSD cases and control groups
Neuropsychological study Structural Neuroimaging study Molecular Neuroimaging study
Case Control Case Control Case Control
Number of individuals for each group 100 100 60 60 25 25
PTSD = Posttraumatic stress disorder; MRI = Magnetic Resonance ImagingPage 8 of 12
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tion. A key aim of the present neuropsychological study is
not only to assess those less explored domains but, also,
try to clarify some discrepancies reported in literature by
examining a more homogeneous, adequately controlled
sample. Some inconsistencies in neuropsychological find-
ings may be attributed at least in part to sample limita-
tions. Neuropsychological deficits involving attention
and memory have been replicated in different samples
including war veterans [14,15,20], rape victims, and other
traumatized populations. However, most neuropsycho-
logical studies of PTSD involve war veterans with chronic
PTSD who frequently exhibit comorbid psychiatric condi-
tions such as depression, anxiety and substance use disor-
ders, which represent major confounders [15]. The effects
of depressed mood on neuropsychological functioning
have been well documented [96]. The high rate of comor-
bidity and overlap of symptoms between these two disor-
ders, however, makes it difficult to exclude individuals
with current depression from PTSD studies. Therefore, it is
important to address the presence of comorbid depres-
sion and to include measures of depression as covariates
in analyses.
Despite the unquestionable progress in identification of
neurocognitve and neuroanatomical abnormalities asso-
ciated with PTSD over the past decade or so, it remains
unclear whether neurostructural and neuropsychological
alterations are specific to PTSD or are related to unspecific
environmental factors such as stress and substance abuse.
The findings from this neuropsychological study, together
with data from neurostructural investigation, may offer an
uncommon opportunity to examine the convergence of
cognitive and neuroanatomical alterations in patients
with PTSD. Stress-induced functional and structural alter-
ations in hippocampus and OFC may mediate many of
the symptoms of PTSD that are related to memory dysreg-
ulation and hyperexcitability. Interestingly, reversion of
both neuropsychological and neuroanatomical abnor-
malities has been demonstrated after treatment with par-
oxetine, which in turn has been shown to promote
neurogenesis in animal studies [97]. The increasing use of
sophisticated neuroimaging techniques is certainly
enhancing our understanding of PTSD, potentially
improving prevention, treatment, and cognitive rehabili-
tation programs [23].
Although a previous study showed involvement of DAT
gene in PTSD [67], and other indirect investigations have
suggested a connection between dopaminergic system
and stress [61], insufficient research has been done on the
role of the DAT in relation to PTSD. To the best of our
knowledge this will be the first SPECT study investigating
dopamine transporter density in patients with PTSD and
well matched resilient controls coming from an epidemi-
ologic sample. The results of this study will help to disen-
tangle whether possible dopaminergic changes in PTSD
are a "state condition" or a "trait" marker of this disorder,
raising a discussion why some subjects exposed to trauma
develop PTSD and some others do not. Moreover, further
studies evaluating patients with PTSD, resilient controls
and healthy control subjects (who never experienced
trauma) would provide useful information to clarify
whether dopaminergic abnormalities are related to PTSD
itself or to psychological trauma exposure.
Advances in molecular imaging techniques, such as
SPECT, have made important contributions to the under-
standing of the pathophysiology of neuropsychiatric dis-
orders [98]. Molecular imaging approaches are more
sensitive than Neuroanatomical imaging techniques, and
are able to identify subtle cerebral pathophysiological
changes before neurostructural abnormalities take place.
One of the major goals of molecular imaging research has
been the identification of biomarkers, which are defined
as the characteristics that are objectively measured and
can differentiate normal biologic processes from patho-
genic processes. These approaches has the potential to
provide accurate and early neuropsychiatric recognition,
evaluate disease progression, and monitor treatment effi-
cacy [68].
These studies have several important limitations. First,
cases are recruited after they have developed PTSD.
Assuming we find differences between cases and controls
on neuropsychological/imaging variables, we will not be
able to determine whether these differences reflect a risk
factor or a consequence of the disorder. Second, in several
situations both cases and controls, were exposed to trau-
matic experience years before the investigations, produc-
ing a potential recall bias.
This study protocol intends to be helpful for researchers
and clinicians interested in designing and/or conducting
translational research in the field of trauma and posttrau-
matic stress disorder.
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